Render Target: STATIC
Render Timestamp:
4/4/2025, 3:27:08 PM EDT
4/4/2025, 7:27:08 PM UTC
Commit: c91f970ca8df4f527662a05c7bd6e4d03c6fa173
XML generation date: 2025-03-07 13:17:04.872
Product last modified at: 2025-01-01T09:04:09.516Z
Cell Signaling Technology Logo

Basket Updated

0

Items added

1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD22 (E8I1F) Rabbit mAb #50825

Filter:
  • WB
Western Blotting Image 1: CD22 (E8I1F) Rabbit mAb
Western blot analysis of extracts from various cell lines using CD22 (E8I1F) Rabbit mAb (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower).

To Purchase # 50825

Cat. # Size Qty. Price
50825T 20 µl
$153
50825S 100 µl
$339

Supporting Data

REACTIVITY M R
SENSITIVITY Endogenous
MW (kDa) 140
Source/Isotype Rabbit IgG
Application Key:
  • WB-Western Blotting 
Species Cross-Reactivity Key:
  • M-Mouse 
  • R-Rat 
  • Related Products

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

CD22 (E8I1F) Rabbit mAb recognizes endogenous levels of total CD22 protein.

Species Reactivity:

Mouse, Rat

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp323 of mouse CD22 protein.

Background

CD22 (also known as siglec-2) is a member of the sialic acid-binding immunoglobulin-type lectin (Siglec) family of immunomodulatory receptors. CD22 can bind to its ligand α 2,6-linked sialic acid on different cells (trans interaction) as well as on the same cells (cis interaction). CD22 is predominantly expressed on B cells and functions as an inhibitory co-receptor for the B cell receptor (BCR) (1,2). After BCR ligation, the tyrosine kinase Lyn is activated and phosphorylates two distal of the four ITIM motifs in the intracellular carboxy-terminal region of CD22, which then recruit tyrosine phosphatases, including SHP-1, to the plasma membrane, and in turn, they get tyrosine-phosphorylated and activated to damp the signaling pathways initiated by BCR ligation (3,4). CD22 has been actively pursued as a therapeutic target for autoimmune diseases (5). Due to almost exclusive expression on B cells, it is also actively pursued as a therapeutic target for multiple B cell malignancies (6-8).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.